An aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer
Open Access
- 21 May 2014
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 136
Abstract
To clarify the roles of a new aberrantly spliced transcript of FAK that lacks exon 26 (denoted -26-exon FAK) in human breast cancers. Transcripts of FAK expressed in 102 human breast tumor tissues and 52 corresponding normal tissues were analyzed by RT-PCR and DNA sequencing, as well as agarose gel electrophoresis. The cDNA of -26-exon FAK was cloned and expressed in MCF-10A cells, and then the kinase activity, cellular localization and migration capability of FAK were examined by western blotting, immunofluorescent staining and migration assays, respectively. The expression levels of FAK were analyzed by western blotting in MCF-7 cells treated with TNF-α or in MCF-10A cells upon serum deprivation. The MCF-10A cells transfected with a plasmid expressing -26-exon FAK were cultured in serum-free medium and cell apoptosis was analyzed by flow cytometry. The -26-exon FAK transcript was exclusively present in human breast tumor tissues and the encoded protein possessed the same kinase activity, cellular localization and cell migration-promoting ability as wild-type FAK. In MCF-7 cells treated with TNF-α, and in MCF-10A cells upon serum deprivation, the -26-exon FAK was resistant to proteolysis while wild-type FAK was largely cleaved. In addition, the -26-exon FAK, but not wild-type FAK, inhibited cell apoptosis. The -26-exon FAK transcript, which is exclusively expressed in human breast tumor tissues, encodes a protein that possesses the same kinase activity and biological function as the wild-type FAK, but because it is resistant to the caspase-mediated cleavage that induces the proteolysis of the wild-type form, it ultimately prevents apoptosis.Keywords
This publication has 16 references indexed in Scilit:
- Caspase control: protagonists of cancer cell apoptosis.2012
- Targeting focal adhesion kinase signaling in tumor growth and metastasisExpert Opinion on Therapeutic Targets, 2009
- Focal adhesion kinase: A potential target in cancer therapyBiochemical Pharmacology, 2007
- Organization and post-transcriptional processing of focal adhesion kinase geneBMC Genomics, 2006
- The role of focal-adhesion kinase in cancer — a new therapeutic opportunityNature Reviews Cancer, 2005
- Focal Adhesion Kinase Suppresses Apoptosis by Binding to the Death Domain of Receptor-Interacting ProteinMolecular and Cellular Biology, 2004
- Caspase-mediated Cleavage of Focal Adhesion Kinase pp125FAK and Disassembly of Focal Adhesions in Human Endothelial Cell ApoptosisJournal of Experimental Medicine, 1998
- Control of adhesion-dependent cell survival by focal adhesion kinase.Journal of Cell Biology, 1996
- Paxillin, a tyrosine phosphorylated focal adhesion-associated protein binds to the carboxyl terminal domain of focal adhesion kinase.Molecular Biology of the Cell, 1995
- Autonomous expression of a noncatalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK.Molecular and Cellular Biology, 1993